Examining the effectiveness of antipsychotic medication in first-episode psychosis

Journal of Psychopharmacology

Volumn 26, Issue , 2012, Pages 27-32

  Taylor, Mark ^a   Cavanagh, Jonathan ^b   Hodgson, Richard ^c   Tiihonen, Jari ^d,e  

^a Ballenden House   (United Kingdom)

^b SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^c Lyme Brook Centre   (United Kingdom)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Antipsychotic; effectiveness; first episode psychosis

Indexed keywords

NEUROLEPTIC AGENT;

HUMAN; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; HUMANS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84866239809     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112439252     Document Type: Review

References (44)

1. Als-Nielsen Bl Chen W Gluud C Kjaergard L (2003) Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 290(7): 921–928.
2. Barnes TRE (2011) Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 25(5): 567–620.
3. Bleuler E (1911) Dementia Praecox or the Group of Schizophrenias (trans Zinkin J, 1950). New York: International Universities Press.
4. Citrome L Stroup ST (2006) Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract 60(8): 933–940.
5. Crossley N Constante M McGuire P Power P (2010) Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Brit J Psychiatry 196: 434–439.
6. Davis J Chen N Glick I (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60: 553–564.
7. Davis JM Chen N Glick ID (2008) Issues that may determine the outcome of antipsychotic trials: industry sponsorship and extrapyramidal side effect. Neuropsychopharmacology 33: 971–975.
8. Farooq S Taylor M (2011) Clozapine: dangerous orphan or neglected friend? Brit J Psychiatry 198: 247–249
9. Fleischhacker WW McQuade RD Marcus RN Archibald D Swanink R Carson WH (2009) A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry 15: 510–517.
10. Gau S Ching-Hu C Churn-Shiouh G (2008) A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in Taiwan. J Clin Psychopharm 28(3): 271–278.
11. Geddes J Freemantle N Harrison P Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J 321: 1371–376.
12. Hegarty JD Baldessarini RJ Tohen H. (1994) One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 151: 1409–1416.
13. Heres S Davis J Maino K. (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head to head comparison studies of second-generation antipsychotics. Am J Psychiatry 163(2): 185–194.
14. Hodgson RE Belgamwar R MacKenzie G Al-tawarah Y (2005) The use of atypical antipsychotics in the treatment of schizophrenia in North Staffordshire. Hum Psychopharmacol 20: 141–147.
15. Hodgson RE Bushe C Hunter R (2007) Measurement of long-term outcomes in observational and randomized controlled trials. Brit J Psychiatry S50: s78–s84.
16. Isohanni M Makikyro T Moring J. (1997) A comparison of clinical and research DSM-III-R diagnoses of schizophrenia in a Finnish national birth cohort. Clinical and research diagnoses of schizophrenia. Soc Psychiatry Psychiatr Epidemiol 32: 303–308.
17. Jones PB Barnes TRE Davies L (2006) Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63: 1079–1087.
18. Kahn RS Fleischhacker WW Boter H. (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. The Lancet 371: 1085–1097.
19. Kendall T (2011) The rise and fall of the atypical antipsychotics. Brit J Psychiatry 199: 266–268.
20. Kraepelin E (1913) Dementia praecox and paraphrenia (trans Barclay RM, 1921). Edinburgh: Livingstone.
21. Langfeldt G (1937) The prognosis in schizophrenia and the factors influencing the course of the disease. Acta Psychiatr Neurol Scand 113(Suppl): 7–228.
22. Leucht S Corves C Arbter D Engel RR Li C Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31–41.
23. Lewis SW Barnes TRE Davies L (2006) Randomised control trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 32: 715–723.
24. Lieberman JA Phillips M Gu H. (2003) Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28: 995–1003.
25. Lieberman JA Stroup TS McEvoy JP. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209–1223.
26. McEvoy JP Lieberman J Perkins D. (2007) Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164(7): 1050–1060.
27. Mallinckrodt CH Sanger TM Dube S. (2003) Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry 15: 754–760.
28. Malamud W Render N (1938) Course and prognosis in schizophrenia. Am J Psychiatry 95: 1039–1057.
29. National Institute for Clinical Excellence (2002) Guidance on the Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. London: NICE.
30. Owens DC (2008) How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia. Adv Psychiatr Treat 14: 17–28.
31. Patel MX David AS (2007) Medication adherence: predictive factors and enhancement strategies. Psychiatry 6(9): 357–361.
32. Robinson D Woerner MG Alvir JM. (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56: 241–247.
33. Sartorius N Leff J Jablensky A. (1987) The International Pilot Study of Schizophrenia: Five year follow-up findings. In: Hafner H Gattaz WF Janzarik W (eds) Search for the Causes of Schizophrenia. Heidelberg: Springer, pp 107–113.
34. Shepherd M Watt D Falloon I Smeeton N (1989) The natural history of schizophrenia: A five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychol Med (Monograph Supplement) 15: 1–46.
35. Stroup TS Lieberman JA McEvoy JP. (2006) Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163: 611–622.
36. Suvisaari JM Haukka JK Tanskanen AJ Lönnqvist JK (1999) Decline in the incidence of schizophrenia in Finnish cohorts born from 1954 to 1965. Arch Gen Psychiatry 56: 733–740.
37. Taylor M Shajahan P Lawrie S (2008) Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. J Clin Psychiatry 69(2): 240–245.
38. Tiihonen J Lönnqvist J Wahlbeck K. (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374(9690): 620–627.
39. Tiihonen J Wahlbeck K Lonnqvist J. (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of 2230 patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. Br Med J 333(7561): 224.
40. Thornley B Adams C (1998) Content and quality of 2000 controlled trials in schizophrenia over 50 years. Br Med J 317: 1181–1184.
41. Tsuang MT Woolson RF Fleming JA (1979) Long-term outcome of major psychoses. I. Schizophrenia and affective disorders compared with psychiatrically symptom-free surgical conditions. Arch Gen Psychiatry 36: 1295–1301.
42. von Knorring L Lindstrom (1995) Principal components and further possibilities with the PANSS. Acta Psychiatrica Scandinavica Supplementum 388: 5–10.
43. Warner R (1994) Recovery from schizophrenia: psychiatry and political economy. London: Psychology Press, Taylor & Francis Group.
44. Wyatt RJ (1991) Neuroleptics and the natural course of schizophrenia. Schizophr Bull 17: 325–351